


Figure 4. Sensitivity analysis varying the number of anti-VEGF injections per year and cost of each injection using a willingness-to-pay of \$50,000



Base cost of ranibizumab and number of injections shown in white dot. Base cost of bevacizumab and number of injections shown in black dot.

L = laser photocoagulation only; L+T = laser photocoagulation plus intravitreal triamcinolone; L + anti-VEGF = laser photocoagulation along with an anti-VEGF agent; DL + anti-VEGF = delayed laser photocoagulation along with an anti-VEGF agent; VEGF = vascular endothelial factor

This figure shows shaded regions that represent which therapy choice is the most cost-effective for different assumptions of number of injections and costs of injections with anti-VEGF therapies. Health benefits are valued at \$50,000.